045  Effect of siponimod on cortical grey matter and thalamic volume in secondary progressive multiple sclerosis

BackgroundGrey matter (GM) loss is associated with cognitive decline and physical disability in multiple sclerosis (MS). In Phase 3 EXPAND study, siponimod significantly reduced disability progression, cognitive decline and whole brain volume loss in patients with secondary progressive MS (SPMS).Met...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology, neurosurgery and psychiatry Vol. 93; no. 6; p. A27
Main Authors: Arnold, Douglas L, Fox, Robert J, Bar-Or, Amit, Cree, Bruce AC, Giovannoni, Gavin, Gold, Ralf, Vermersch, Pat- rick, Meier, Daniela Piani, Arnould, Sophie, Kappos, Ludwig
Format: Journal Article
Language:English
Published: London BMJ Publishing Group Ltd 01.06.2022
BMJ Publishing Group LTD
Subjects:
ABN Abstracts 2020
Magnetic resonance imaging
Multiple sclerosis
ISSN:0022-3050, 1468-330X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundGrey matter (GM) loss is associated with cognitive decline and physical disability in multiple sclerosis (MS). In Phase 3 EXPAND study, siponimod significantly reduced disability progression, cognitive decline and whole brain volume loss in patients with secondary progressive MS (SPMS).MethodsMagnetic resonance imaging (MRI) from EXPAND were pooled and analysed using high reso- lution T1 and conventional MRI. Analysis included intent-to-treat population (full analysis set, FAS) and per protocol set (PPS). Change from baseline in cortical grey matter (cGM) and thalamic volumes were assessed.ResultsIn the FAS, adjusted mean percent change in volume from baseline at M12 and M24, respectively, was −0.07 versus −0.59 (88% reduction vs placebo, p<0.0001) and −0.51 versus −0.90 (43% reduction; p<0.0001) for cGM; −0.54 versus −1.01 (47% reduction; p< 0.0001) and −1.20 versus −1.74 (31% reduction; p=0.0001) for the thalamus. PPS values were 0.01 versus −0.60 (100% reduction; p< 0.0001) and −0.39 versus−1.04 (63% reduction; p< 0.0001) for cGM; −0.47 vs −0.94 (50% reduction; p< 0.0001) and −1.02 versus −1.77 (42% reduction; p< 0.0001) for the thalamus.ConclusionsSiponimod significantly reduced cGM and thalamic volume loss compared with placebo in patients with SPMS.g.giovannoni@qmul.ac.uk
Bibliography:Poster Presentations
ObjectType-Conference Proceeding-1
SourceType-Scholarly Journals-1
content type line 14
ISSN:0022-3050
1468-330X
DOI:10.1136/jnnp-2022-ABN.84